Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | LCK | P06239 | 3/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 7/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.53 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946622 | 0.88 | BTK (0.67) | KITMAPK14KDRLCKSRC | |
| SCHEMBL3086176 | 0.84 | MAPT (0.58) | BRAFEIF2AK3EIF2AK4KDM4EMEN1 | |
| SCHEMBL2950917 | 0.83 | KIT (1.00) | KITMAPK14KDRLCKSRC | |
| SCHEMBL3085908 | 0.82 | MAPT (0.57) | BRAFEIF2AK3EIF2AK4KDM4EMEN1 | |
| SCHEMBL2951773 | 0.82 | KDR (1.00) | KITMAPK14KDRLCKSRC | |
| SCHEMBL15679154 | 0.81 | BTK (0.52) | KITMAPK14KDRLCKSRC | |
| SCHEMBL3937838 | 0.81 | BRAF (0.76) | KITMAPK14KDRLCKSRC | |
| SCHEMBL3300395 | 0.80 | MAPT (0.55) | BRAFKDM4EMEN1CYP2D6MAPT | |
| SCHEMBL3300398 | 0.80 | MAPT (0.54) | BRAFEIF2AK3EIF2AK4KDM4EMEN1 | |
| SCHEMBL2947747 | 0.79 | KIT (0.67) | KITMAPK14KDRLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | KIT 7/4885MAPK14 525/4885KDR 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.